Last updated: 2026-10-14 21:45:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
BioLife Solutions Inc. (BLFS) operates in the ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $38.60, with a market capitalisation of $1.89B and a P/E ratio of 32.58. Over the past 52 weeks, its price has ranged from $17.86 to $39.76. This page covers its latest market performance, valuation, price trends and company information.
$1.89B | |
$37.16 | |
$60.67 | |
$1.43 | |
$37.30 | |
3.94M | |
1.14M | |
32.58 | |
$39.76 | |
$17.86 | |
-- | |
-- |
BioLife Solutions Inc. (BLFS) is trading at $38.60 in after-hours trading as of 2026-10-05 23:31:00, up 3.49% ($1.30) from the regular-session close of $37.30.
After-hours trading shows how investors are pricing BLFS after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, BioLife Solutions Inc. (BLFS) moved from $38.49 to $38.60, representing a gain of 0.27% ($0.10).
The stock traded between $36.70 and $39.76 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 1.74 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 94.7%
BLFS is currently trading at $38.60, placing it 94.7% of the way from its 52-week low of $17.86 to its 52-week high of $39.76. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
| Industry | ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS |
| Employees | 155 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BioLife Solutions Inc. (BLFS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.